Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?

Lancet Oncol. 2011 Feb;12(2):118. doi: 10.1016/S1470-2045(11)70017-1.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelomonocytic, Chronic / drug therapy*
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate